trending Market Intelligence /marketintelligence/en/news-insights/trending/ixqzlesyfb-4jtesytqzgw2 content esgSubNav
In This List

Achillion Pharmaceuticals appoints former uniQure exec as COO

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Achillion Pharmaceuticals appoints former uniQure exec as COO

Achillion Pharmaceuticals Inc. named Paul Firuta to the positions of executive vice president and COO, effective Sept. 10.

Firuta most recently served as the chief commercial officer of uniQure NV, an Amsterdam-based gene-editing company.

Prior to joining uniQure, Firuta was the president of U.S. commercial operations in Bedminster, N.J.-based NPS Pharmaceuticals Inc., a biopharmaceutical company that develops treatments for gastrointestinal and endocrine disorders.

New Haven, Conn.-based Achillion Pharmaceuticals is focused on developing its oral factor D inhibitors to treat rare diseases with no or inadequate approved therapies.